News
![SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
SOLIRIS® (eculizumab) Receives Approval in Japan for the Prevention of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the extension of the current marketing authorization of SOLIRIS®
![FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions
Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the
![Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals
The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly
![Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination
Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be
![Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic
![Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Biogen: Neue Hoffnung auf ein Alzheimer-Medikament treibt Aktie an!
Einer der größten Gewinner am US-Aktienmarkt war gestern das Papier von Biogen (WKN: 789617). Grund hierfür waren jedoch nicht in erster Linie die vorgelegten, sehr guten Quartalszahlen, sondern
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Form 8.3 - The Vanguard Group, Inc.: AbbVie plc](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc
![Entpuppt sich Gilead Sciences doch noch als Value Trap?](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Entpuppt sich Gilead Sciences doch noch als Value Trap?
![Here's How AbbVie Inc. Crushed It in 2017](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Here's How AbbVie Inc. Crushed It in 2017
![3 Reasons to Own Pfizer's Stock in 2018](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
3 Reasons to Own Pfizer's Stock in 2018
![Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb
![Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Better Stock: AbbVie (ABBV) vs. Eli Lilly (LLY)
![If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
If I Could Only Buy 1 Healthcare Stock in January, It Would Be This One
![3 Promising Cancer Immunotherapies to Watch in 2018](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
3 Promising Cancer Immunotherapies to Watch in 2018
![3 Top Generic Drug Stocks to Consider Buying Now](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
3 Top Generic Drug Stocks to Consider Buying Now
![New Gene Therapies Could Change Hemophilia Forever](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
New Gene Therapies Could Change Hemophilia Forever
![3 Top Pharmaceutical Dividend Stocks to Buy Now](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
3 Top Pharmaceutical Dividend Stocks to Buy Now
![This Possible Dog of the Dow Just Got Even More Interesting](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
This Possible Dog of the Dow Just Got Even More Interesting
![Why 2017 Was a Year to Remember for Johnson & Johnson](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Why 2017 Was a Year to Remember for Johnson & Johnson
![The 5 Best-Selling Drugs of 2017](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
The 5 Best-Selling Drugs of 2017
![3 Top Dividend Aristocrats to Buy for 2018](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
3 Top Dividend Aristocrats to Buy for 2018
![Better Buy: Johnson & Johnson vs. Merck](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Better Buy: Johnson & Johnson vs. Merck
![Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)